Exopharm Share Price and Company Fundamentals
Last traded: Today at 5:48 AM
Exopharm Limited, a clinical-stage company, develops transformative medicines based upon extracellular vesicles (EVs) in Australia. The company's technology includes extracellular vesicle positioning system that allows specific molecules to be attached to the surface of exosomes to guide them to target tissues or cell types; leveraging oligonucleotide packing for amplified dosing, which enables specific RNA molecules to be preferentially loaded into exosomes as a therapeutic cargo; ligand-based exosome affinity purification that isolates and purifies exosomes from biofluids like blood and cell culture media. Its engineered EVs products comprise Fortrexo CoV for the treatment of SARS-CoV-2 infection; Cognevo for the treatment of neuro degeneration; and PlexoDox for the treatment of cancer. Exopharm Limited has a research collaboration with Showa Denko Materials Co., Ltd. The company was incorporated in 2013 and is based in Melbourne, Australia.
|Primary activities||Biopharmaceutical research with a primary focus on developing and commercialising exosomes as therapeutic agents.|
|Industry / Sector||Biotechnology / Healthcare|
|Full time employees||41|
|Mailing address||31 Queen Street Level 17 Melbourne VIC 3000 Australia|
|Phone / Fax||61 3 9111 0026 /|
|Share registry||AUTOMIC REGISTRY SERVICES|
Exopharm does not pay dividends.
As of Sep 2021, following are the company executives and directors listed on Exopharm.
|Dr. Ian E. Dixon M.A.I.C.D., M.B.A., MBA, Ph.D.||Founder, Technology Co-Founder, CEO MD & Director||430.38k|
|Dr. Gregor Lichtfuss M.Sc.||Co-Founder & Bus. Services Mang.||228.54k|
|Dr. Christopher Baldwin Ph.D.||Deputy CEO & Chief Commercial Officer||377.56k|
|Ms. Elizabeth McGregor B.A., M.B.A.||Company Sec. & Non-Exec. Director||36.81k|
|Mr. David Oxley||Pres of International|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Exopharm is 73.89M and its enterprise value is 60.11M. The enterprise value to revenue ratio of EX1 is 14.34.
The EX1's stocks Beta value is 0.96 making it 4% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Exopharm (EX1)
Exopharm (ASX:EX1) Frequently Asked Questions
1. What is Exopharm's Stock Symbol?
Exopharm trades on ASX under the ticker symbol "EX1".
2. What is Exopharm's stock price today?
One share of EX1 stock can currently be purchased for approximately $0.47.
3. How can I contact Exopharm?
Exopharm's mailing address is 31 Queen Street Level 17 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 3 9111 0026.
4. What is Exopharm's official website?
The official website of Exopharm is http://www.exopharm.com.
5. Which share registry manages Exopharm's stock?
Exopharm's stock is managed by AUTOMIC REGISTRY SERVICES.